Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice

Author(s):
Mulder, P.; Morrison, M.C.; Verschuren, L.; Liang, W.; Bockel, J.H. van; Kooistra, T.; Wielinga, P.Y.; Kleemann, R.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-08-22
Language
English
Is part of
Scientific Reports
hdl
1887/114028
doi
10.1038/srep31542